Nivolumab vs Pembrolizumab

## Nivolumab vs Pembrolizumab: Overview

This comparison examines the pharmacological differences between **Nivolumab** and **Pembrolizumab**.

## Mechanism of Action

**Nivolumab**: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

**Pembrolizumab**: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

## Pharmacokinetics

**Half-life**: Nivolumab — 27 days; Pembrolizumab — 26 days.

## Chemical Properties

**Type**: Nivolumab — Antibody; Pembrolizumab — Antibody.